New combo aims to prevent transplant complications
NCT ID NCT04886726
First seen Feb 26, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-phase study tests whether adding two natural proteins (uhCG/EGF) to standard post-transplant chemotherapy can safely prevent graft-versus-host disease (GVHD) in patients receiving stem cells from partially matched donors. About 18 adults with blood cancers who lack a fully matched donor will participate. The main goal is to find the safest dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Hospital
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.